

## UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

#27

NOV 2 2 1994

Mark P. Levy, Esq. Thompson, Hine & Flory 2000 Courthouse Plaza, N.E. P.O. Box 8801 Dayton, OH 45401-8801 Re:

Patent Term Extension

Application for

U.S. Patent No. 4,219,478

## NOTICE OF FINAL DETERMINATION

A determination has been made that U.S. Patent No. 4,219,478 issued August 26, 1980, which claims the human drug product Mycobutin, is eligible for patent term extension under 35 USC § 156. The period of extension has been determined to be 1,406 days.

The period of extension has been calculated using the FDA determination of the length of the regulatory review period published in the Federal Register of April 15, 1994, as amended on June 14, 1994. Under 35 USC § 156(c):

Period of Extension = 1/2 (Testing Phase) + Approval Phase = 1/2 (2,127) + 342 = 1,406 days

Since the regulatory review period began after the patent issue date, the entire period has been considered in the above calculation. No determination of a lack of due diligence was made.

The limitation of 35 USC § 156(g)(6) and the 14 year exception of 35 USC § 156(c)(3) do not operate to reduce the period determined above.

A single request for reconsideration of this final determination as to the length of extension of the term of the patent may be made if filed within one month of the date of this notice. Extensions of time under 37 CFR § 1.136(a) are not applicable to this time period. In the absence of such request for reconsideration, the Commissioner will issue to the applicant for extension of the term of Patent No. 4,219,478 a certificate of extension, under seal, for a period of 1,406 days.

## U.S. Patent No. 4,219,478

Upon issuance of the certificate of extension the following information will be published in the Official Gazette:

U.S. Patent No.:

4,219,478

Granted:

August 26, 1980

Applicant:

Leonardo Marsili et al.

Owner of Record:

Farmitalia Carlo Erba S.r.l.

Title:

RIFAMYCIN COMPOUNDS

Classification:

540/453

Product Trade Name:

Mycobutin

Term Extended:

1,406 days

Gerald A. Dost

Special Program Examiner

Office of Special Programs

Office of the Deputy Assistant Commissioner

for Patent Policy and Projects

(703) 305-9282

cc:

Ronald L. Wilson, Director Health Assessment Policy Staff Office of Health Affairs (HFY-20) Food and Drug Administration 5600 Fishers Lane, Room 11-44 Rockville, MD 20857 RE: Mycobutin

FDA Docket No.: 93E - 0099